title: The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers.
authors.forename: Anne
authors.initials: A
authors.lastname: Kirsten
authors.forename: Henrik
authors.initials: H
authors.lastname: Watz
authors.forename: Frauke
authors.initials: F
authors.lastname: Pedersen
authors.forename: Olaf
authors.initials: O
authors.lastname: Holz
authors.forename: Rachel
authors.initials: R
authors.lastname: Smith
authors.forename: Gerard
authors.initials: G
authors.lastname: Bruin
authors.forename: Stephan
authors.initials: S
authors.lastname: Koehne-Voss
authors.forename: Helgo
authors.initials: H
authors.lastname: Magnussen
authors.forename: David A
authors.initials: DA
authors.lastname: Waltz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology*; D007960:Leukocyte Disorders / Q000139:chemically induced* / Q000188:drug therapy*; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D010126:Ozone / Q000009:adverse effects*; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D010126:Ozone; C555450:secukinumab